邦顺制药递表港交所 专注于肿瘤及自身免疫性疾病领域

Company Overview - Hangzhou Bangshun Pharmaceutical Co., Ltd. (Bangshun Pharmaceutical) is a biotechnology company focused on oncology and autoimmune diseases, with a pipeline that includes one new drug application (NDA) candidate (Bezeixinib), one clinical-stage candidate (CX1440), and five preclinical candidates (CX03, CX12, CX13, CX15, and CX16) [3] - Bezeixinib is expected to be one of the first three domestically approved JAK inhibitors for treating myelofibrosis (MF) in China, with clinical trials ongoing for MF, polycythemia vera (PV), and essential thrombocythemia (ET) [3] - CX1440 is a leading BTK inhibitor for treating immune thrombocytopenia (ITP) and is in Phase III clinical trials, with significant market potential in ITP, chronic urticaria (CU), and autoimmune hemolytic anemia (AIHA) [4] Financial Information - For the fiscal year 2024, Bangshun Pharmaceutical reported revenues of approximately CNY 943,000, with losses of approximately CNY 88.44 million [5][6] - The company has only one customer during the reporting period, and its revenue primarily comes from technology transfers related to preclinical projects [4] Industry Overview - The global market for myeloproliferative neoplasms (MPN) is projected to grow from USD 6.6 billion in 2020 to USD 8.3 billion in 2024, with a compound annual growth rate (CAGR) of 6.0%, and is expected to reach USD 12.7 billion by 2030 [8] - The Chinese MPN drug market is also growing, with a projected increase from USD 700 million in 2020 to USD 900 million in 2024, and expected to reach USD 1.6 billion by 2030 [8] - The market for JAK inhibitors in MF is expected to reach USD 300 million in China by 2024, with a CAGR of 3.5% from 2020 to 2024 [11] - The global market for PV drugs is anticipated to grow from USD 2.1 billion in 2020 to USD 2.7 billion in 2024, with a CAGR of 6.5% [13] - The market for autoimmune disease drugs in China is projected to grow from USD 2.5 billion in 2020 to USD 4.6 billion in 2024, with a CAGR of 15.9% [19]